Literature DB >> 31131906

Reliability of tumor segmentation in glioblastoma: Impact on the robustness of MRI-radiomic features.

Florent Tixier1, Hyemin Um1, Robert J Young2,3, Harini Veeraraghavan1.   

Abstract

PURPOSE: The use of radiomic features as biomarkers of treatment response and outcome or as correlates to genomic variations requires that the computed features are robust and reproducible. Segmentation, a crucial step in radiomic analysis, is a major source of variability in the computed radiomic features. Therefore, we studied the impact of tumor segmentation variability on the robustness of MRI radiomic features.
METHOD: Fluid-attenuated inversion recovery (FLAIR) and contrast-enhanced T1-weighted (T1WICE ) MRI of 90 patients diagnosed with glioblastoma were segmented using a semiautomatic algorithm and an interactive segmentation with two different raters. We analyzed the robustness of 108 radiomic features from five categories (intensity histogram, gray-level co-occurrence matrix, gray-level size-zone matrix (GLSZM), edge maps, and shape) using intra-class correlation coefficient (ICC) and Bland and Altman analysis.
RESULTS: Our results show that both segmentation methods are reliable with ICC ≥ 0.96 and standard deviation (SD) of mean differences between the two raters (SDdiffs ) ≤ 30%. Features computed from the histogram and co-occurrence matrices were found to be the most robust (ICC ≥ 0.8 and SDdiffs  ≤ 30% for most features in these groups). Features from GLSZM were shown to have mixed robustness. Edge, shape, and GLSZM features were the most impacted by the choice of segmentation method with the interactive method resulting in more robust features than the semiautomatic method. Finally, features computed from T1WICE and FLAIR images were found to have similar robustness when computed with the interactive segmentation method.
CONCLUSION: Semiautomatic and interactive segmentation methods using two raters are both reliable. The interactive method produced more robust features than the semiautomatic method. We also found that the robustness of radiomic features varied by categories. Therefore, this study could help motivate segmentation methods and feature selection in MRI radiomic studies.
© 2019 American Association of Physicists in Medicine.

Entities:  

Keywords:  MRI; glioblastoma; radiomics; robustness; segmentation

Year:  2019        PMID: 31131906      PMCID: PMC6692188          DOI: 10.1002/mp.13624

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  15 in total

1.  The Pursuit of Generalizability to Enable Clinical Translation of Radiomics.

Authors:  Pallavi Tiwari; Ruchika Verma
Journal:  Radiol Artif Intell       Date:  2020-12-16

2.  Radiomics feature reproducibility under inter-rater variability in segmentations of CT images.

Authors:  Christoph Haarburger; Gustav Müller-Franzes; Leon Weninger; Christiane Kuhl; Daniel Truhn; Dorit Merhof
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

3.  Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics.

Authors:  Alexandre Carré; Guillaume Klausner; Myriam Edjlali; Marvin Lerousseau; Jade Briend-Diop; Roger Sun; Samy Ammari; Sylvain Reuzé; Emilie Alvarez Andres; Théo Estienne; Stéphane Niyoteka; Enzo Battistella; Maria Vakalopoulou; Frédéric Dhermain; Nikos Paragios; Eric Deutsch; Catherine Oppenheim; Johan Pallud; Charlotte Robert
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

4.  Robustness of radiomic features in CT images with different slice thickness, comparing liver tumour and muscle.

Authors:  Eva Mendes Serrao; Evis Sala; Lorena Escudero Sanchez; Leonardo Rundo; Andrew B Gill; Matthew Hoare
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.996

5.  Anterior Mediastinal Lesion Segmentation Based on Two-Stage 3D ResUNet With Attention Gates and Lung Segmentation.

Authors:  Su Huang; Xiaowei Han; Jingfan Fan; Jing Chen; Lei Du; Wenwen Gao; Bing Liu; Yue Chen; Xiuxiu Liu; Yige Wang; Danni Ai; Guolin Ma; Jian Yang
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

6.  Reproducibility analysis of multi-institutional paired expert annotations and radiomic features of the Ivy Glioblastoma Atlas Project (Ivy GAP) dataset.

Authors:  Sarthak Pati; Ruchika Verma; Hamed Akbari; Michel Bilello; Virginia B Hill; Chiharu Sako; Ramon Correa; Niha Beig; Ludovic Venet; Siddhesh Thakur; Prashant Serai; Sung Min Ha; Geri D Blake; Russell Taki Shinohara; Pallavi Tiwari; Spyridon Bakas
Journal:  Med Phys       Date:  2020-12-04       Impact factor: 4.071

7.  Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy.

Authors:  Iva Petkovska; Florent Tixier; Eduardo J Ortiz; Jennifer S Golia Pernicka; Viktoriya Paroder; David D Bates; Natally Horvat; James Fuqua; Juliana Schilsky; Marc J Gollub; Julio Garcia-Aguilar; Harini Veeraraghavan
Journal:  Abdom Radiol (NY)       Date:  2020-11

8.  MRI-based radiomics in breast cancer: feature robustness with respect to inter-observer segmentation variability.

Authors:  N M H Verbakel; A Ibrahim; M L Smidt; H C Woodruff; R W Y Granzier; J E van Timmeren; T J A van Nijnatten; R T H Leijenaar; M B I Lobbes
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

9.  Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma.

Authors:  Shuliang Zhao; Yi Su; Jinghao Duan; Qingtao Qiu; Xingping Ge; Aijie Wang; Yong Yin
Journal:  J Bone Oncol       Date:  2019-10-04       Impact factor: 4.072

10.  Correction for Magnetic Field Inhomogeneities and Normalization of Voxel Values Are Needed to Better Reveal the Potential of MR Radiomic Features in Lung Cancer.

Authors:  Maxime Lacroix; Frédérique Frouin; Anne-Sophie Dirand; Christophe Nioche; Fanny Orlhac; Jean-François Bernaudin; Pierre-Yves Brillet; Irène Buvat
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.